Organisation paid for research Program year 2025 Source: CMS Open Payments

Alliance Clinical Network

Neither a doctor nor a teaching hospital

Research payments

$1,425,004

1,712 payments

Through program year 2025, Alliance Clinical Network is reported as receiving $1,425,004 in research payments, across 1,712 payments.

By program year

1 row

Year	Kind	Amount	Payments
2025	Research	$1,425,004	1,712

Breakdown

Who paid Research payments · program year 2025

Ipsen Innovation $1,382,628 1,708 payments
Celgene Corporation $29,025 1 payment
Novartis Pharmaceuticals Corporation $13,351 3 payments

Studies the money was for Research payments · program year 2025

Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants $701,757 943 payments
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants $662,821 760 payments
A Phase 2, Randomized, Double-blind, Three-Arm, Placebo-controlled, Multicenter Study Assessing the Efficacy, Safety and Tolerability of orally administered BMS-986368, a FAAH/MAGL Inhibitor, for the treatment of Agitation in Participants with Alzheimer's Disease $29,025 1 payment
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults $18,050 5 payments
A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) $10,370 1 payment
A randomized double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) in US Black/African American & Hispanic patient populations with elevated Lp(a) and established atherosclerotic cardi $2,526 1 payment
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open-Label Pelacarsen in Participants With Elevated Lp(a) and Established ASCVD $454 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.